Wetherby Asset Management Inc Blueprint Medicines Corp Transaction History

Wetherby Asset Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$54.1 - $110.08 $155,591 - $316,590	-2,876 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$94.25 - $115.99 $2,167 - $2,667	23 Added 0.81%	2,876 $308,000
Q3 2021 Nov 15, 2021	BUY	$80.98 - $109.47 $1,295 - $1,751	16 Added 0.56%	2,853 $293,000
Q2 2021 Aug 16, 2021	BUY	$82.78 - $101.0 $234,846 - $286,537	2,837 New	2,837 $250,000
Q1 2021 May 14, 2021	SELL	$90.71 - $108.28 $266,687 - $318,343	-2,940 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$92.08 - $124.48 $460 - $622	5 Added 0.17%	2,940 $330,000
Q3 2020 Nov 13, 2020	BUY	$66.45 - $92.7 $195,030 - $272,074	2,935 New	2,935 $272,000

350

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.3B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Wetherby Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Wetherby Asset Management Inc with notifications on news.